Precigen has been granted a patent for polynucleotides encoding ligand-inducible gene switch polypeptides, allowing for the modulation of gene expression in host cells. The patent also covers a method for integrating heterologous genes into peripheral blood mononuclear cells using specific recombinase enzymes. GlobalData’s report on Precigen gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Precigen Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Precigen, Cancer treatment biomarkers was a key innovation area identified from patents. Precigen's grant share as of April 2024 was 43%. Grant share is based on the ratio of number of grants to total number of patents.

Method for integrating genes into pbmc genome

Source: United States Patent and Trademark Office (USPTO). Credit: Precigen Inc

A recently granted patent (Publication Number: US11946054B2) discloses a method for integrating heterologous genes into the genome of peripheral blood mononuclear cells (PBMCs). The method involves delivering a non-naturally occurring polynucleotide containing an AttP or AttB recombination sequence along with the heterologous gene(s), and a polynucleotide encoding a serine recombinase such as SF370, SPßc2, Bxb1, A118, or fRv1. The delivery of these polynucleotides can be achieved through various methods like transfection, transformation, nucleofection, or transduction, using techniques like calcium phosphate precipitation, lipofection, particle bombardment, or microinjection.

Furthermore, the patent claims encompass the inclusion of cytokines, cell tags, and fusion proteins in the non-naturally occurring polynucleotide, along with chimeric antigen receptors capable of binding to specific targets like CD19, EGFRvIII, CD33, ROR1, and MUC-16. The chimeric antigen receptors described in the claims have specific amino acid sequences with high identity to certain SEQ ID NOs, allowing for precise targeting and integration into PBMCs. This method opens up possibilities for genetic modifications in immune cells, particularly T cells and NK cells, for potential therapeutic applications in areas like cancer immunotherapy and targeted antigen recognition.

To know more about GlobalData’s detailed insights on Precigen, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies